Granules to market heart burn drug in North America
Granules USA, the wholly owned subsidiary of Granules India Ltd., on Thursday announced that it has signed agreement with Par Pharmaceutical Inc., a subsidiary of Endo International Plc., to market the generic version of omeprazole and sodium bicarbonate in North America. The company expects the US Food and Drug Administration (USFDA) approval for this generic heart burn drug in July 2016. Omeprazole is a proton pump inhibitor (PPI) that decreases the production of stomach acid. Sodium bicarbonate is an antacid that raises stomach pH to keep the Omeprazole from breaking down in stomach acid. “Granules is excited that, through this exclusive agreement with Par Pharmaceuticals, we can strengthen our OTC (over the counter) product basket and widen our offerings in the North American store brand market for meeting retailers’ and consumers’ desire for competitive market choices and alternative,” said Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Ltd. “Continuing to reduce healthcare costs through partnership with retailers, Granules is happy to offer affordable medication choices,” said Robert Fisher, President of Consumer Health division of Granules USA.
January 21, 2015 | 4:39pm IST.
to success.